Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTA1 | P08263 | 6/20 | 0.50 |
| ▸ | GSTP1 | P09211 | 6/20 | 0.50 |
| ▸ | PTPRC | P08575 | 4/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.45 |
| ▸ | PTPRB | P23467 | 4/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.45 |
| ▸ | CD69 | Q07108 | 2/20 | 0.43 |
| ▸ | TLR4 | O00206 | 4/20 | 0.43 |
| ▸ | CD14 | P08571 | 4/20 | 0.43 |
| ▸ | LY96 | Q9Y6Y9 | 4/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL759676 | 0.94 | GSTA1 (0.52) | GSTA1GSTP1PTPRCPTPN2PTPN1 | |
| SCHEMBL6202528 | 0.90 | PTPRC (0.53) | GSTA1GSTP1PTPRCPTPN2PTPN1 | |
| SCHEMBL6067606 | 0.86 | GSTA1 (0.57) | GSTA1GSTP1PTPRCPTPN2PTPN1 | |
| SCHEMBL30702676 | 0.86 | GSTA1 (0.57) | GSTA1GSTP1PTPRCPTPN2PTPN1 | |
| SCHEMBL760971 | 0.78 | GSTA1 (0.65) | GSTA1GSTP1PTPRCPTPN2PTPN1 | |
| SCHEMBL31326111 | 0.76 | GSTA1 (0.56) | GSTA1GSTP1PTPRCPTPN2PTPN1 | |
| SCHEMBL12856857 | 0.76 | GSTA1 (0.56) | GSTA1GSTP1PTPRCPTPN2PTPN1 | |
| SCHEMBL6820489 | 0.76 | PTPRC (0.46) | GSTA1GSTP1PTPRCPTPN2PTPN1 | |
| SCHEMBL761363 | 0.72 | GSTA1 (0.67) | GSTA1GSTP1PTPRCPTPN2PTPN1 | |
| SCHEMBL2108268 | 0.71 | CD69 (0.44) | PTPRCPTPN2PTPN1PTPRBPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481691-B2 | Method for selectively extracting membrane proteins using calixarenes | Centre National de la Recherche Scientifique—CNRS (FR) | 2013-07-09 | — | — | US | disclosed |
| EP-2307116-B1 | METHOD FOR SELECTIVELY EXTRACTING MEMBRANE PROTEINS USING CALIXARENES | CENTRE NAT RECH SCIENT (FR) | 2012-03-21 | — | — | EP | disclosed |
| US-20110144314-A1 | METHOD FOR SELECTIVELY EXTRACTING MEMBRANE PROTEINS USING CALIXARENES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2307116-A1 | METHOD FOR SELECTIVELY EXTRACTING MEMBRANE PROTEINS USING CALIXARENES | Centre National de la Recherche Scientifique - CNRS (FR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009144419-A1 | METHOD FOR SELECTIVELY EXTRACTING MEMBRANE PROTEINS USING CALIXARENES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144314-A1 | METHOD FOR SELECTIVELY EXTRACTING MEMBRANE PROTEINS USING CALIXARENES | CANX, CALD1, CALU | GSTA1 1011/4885GSTP1 1424/4885PTPRC 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.